Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $479.36 billion. The enterprise value is $476.84 billion.
Important Dates
The next confirmed earnings date is Wednesday, February 5, 2025, before market open.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | Aug 16, 2024 |
Share Statistics
Novo Nordisk has 4.45 billion shares outstanding. The number of shares has decreased by -0.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.45B |
| Shares Change (YoY) | -0.86% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.16B |
Valuation Ratios
The trailing PE ratio is 33.84 and the forward PE ratio is 29.17.
| PE Ratio | 33.84 |
| Forward PE | 29.17 |
| PS Ratio | n/a |
| Forward PS | 1.49 |
| PB Ratio | n/a |
| P/TBV Ratio | 48.54 |
| P/FCF Ratio | 44.25 |
| P/OCF Ratio | 27.11 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 23.95, with an EV/FCF ratio of 44.02.
| EV / Earnings | 33.66 |
| EV / Sales | 11.78 |
| EV / EBITDA | 23.95 |
| EV / EBIT | 25.41 |
| EV / FCF | 44.02 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.47.
| Current Ratio | 0.94 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 0.42 |
| Debt / FCF | 0.79 |
| Interest Coverage | 825.54 |
Financial Efficiency
Return on equity (ROE) is 88.73% and return on invested capital (ROIC) is 52.81%.
| Return on Equity (ROE) | 88.73% |
| Return on Assets (ROA) | 22.49% |
| Return on Capital (ROIC) | 52.81% |
| Revenue Per Employee | $629,195 |
| Profits Per Employee | $220,258 |
| Employee Count | 64,319 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.23 |
Taxes
In the past 12 months, Novo Nordisk has paid $3.67 billion in taxes.
| Income Tax | 3.67B |
| Effective Tax Rate | 20.57% |
Stock Price Statistics
The stock price has increased by +4.39% in the last 52 weeks. The beta is 0.17, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +4.39% |
| 50-Day Moving Average | 109.93 |
| 200-Day Moving Average | 126.50 |
| Relative Strength Index (RSI) | 37.79 |
| Average Volume (20 Days) | 4,879,901 |
Short Selling Information
| Short Interest | 5.68M |
| Short Previous Month | 6.05M |
| Short % of Shares Out | 0.18% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.88 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $40.47 billion and earned $14.17 billion in profits. Earnings per share was $3.17.
| Revenue | 40.47B |
| Gross Profit | 34.26B |
| Operating Income | 18.77B |
| Pretax Income | 16.54B |
| Net Income | 14.17B |
| EBITDA | 19.91B |
| EBIT | 18.77B |
| Earnings Per Share (EPS) | $3.17 |
Full Income StatementBalance Sheet
The company has $11.20 billion in cash and $8.52 billion in debt, giving a net cash position of $2.68 billion or $0.60 per share.
| Cash & Cash Equivalents | 11.20B |
| Total Debt | 8.52B |
| Net Cash | 2.68B |
| Net Cash Per Share | $0.60 |
| Equity (Book Value) | 18.03B |
| Book Value Per Share | 4.05 |
| Working Capital | -1.97B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $17.68 billion and capital expenditures -$6.05 billion, giving a free cash flow of $10.83 billion.
| Operating Cash Flow | 17.68B |
| Capital Expenditures | -6.05B |
| Free Cash Flow | 10.83B |
| FCF Per Share | $2.43 |
Full Cash Flow StatementMargins
Gross margin is 84.66%, with operating and profit margins of 46.37% and 35.01%.
| Gross Margin | 84.66% |
| Operating Margin | 46.37% |
| Pretax Margin | 44.07% |
| Profit Margin | 35.01% |
| EBITDA Margin | 49.19% |
| EBIT Margin | 46.37% |
| FCF Margin | 26.77% |
Dividends & Yields
This stock pays an annual dividend of $1.44, which amounts to a dividend yield of 1.40%.
| Dividend Per Share | $1.44 |
| Dividend Yield | 1.40% |
| Dividend Growth (YoY) | 39.22% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 45.51% |
| Buyback Yield | 0.86% |
| Shareholder Yield | 2.26% |
| Earnings Yield | 2.96% |
| FCF Yield | 2.26% |
Dividend DetailsAnalyst Forecast
The average price target for Novo Nordisk is $144.20, which is 39.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $144.20 |
| Price Target Difference | 39.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 13.95% |
| EPS Growth Forecast (5Y) | 16.66% |
Stock ForecastsStock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 10.12 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.12 |
| Piotroski F-Score | 6 |